Previous 10 | Next 10 |
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday bri...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of the Alpine senior leadership team will participate in an analyst-led f...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will participate in a fireside chat at the Piper Sandler 32nd Annual Virtua...
Alpine Immune Sciences, Inc. (ALPN) Q3 2020 Earnings Conference Call November 12, 2020 04:30 PM ET Company Participants Laurence Watts - Investor Relations Mitchell Gold - Chairman & Chief Executive Officer Stanford Peng - President & Head of Research & Development Paul Rickey - C...
Alpine Immune Sciences (ALPN): Q3 GAAP EPS of -$0.28 misses by $0.05.Revenue of $1.91M (+558.6% Y/Y) misses by $14.17M.Press Release For further details see: Alpine Immune Sciences EPS misses by $0.05, misses on revenue
- Conference call and webcast today at 4:30 p.m. ET - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune / inflammatory diseases, today provided a corporate update a...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release third quarter 2020 financial results on Thursday, November 12,...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summi...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...